<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35945502</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2202</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>09</Day></PubDate></JournalIssue><Title>BMC neuroscience</Title><ISOAbbreviation>BMC Neurosci</ISOAbbreviation></Journal><ArticleTitle>Spatiotemporal evolution of pyroptosis and canonical inflammasome pathway in hSOD1<sup>G93A</sup> ALS mouse model.</ArticleTitle><Pagination><StartPage>50</StartPage><MedlinePgn>50</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">50</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12868-022-00733-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">Evidences indicate that inflammasome compounds participate in amyotrophic lateral sclerosis (ALS), a fatal progressive motoneuron degenerative disease. Researchers have observed the expressions of nucleotide oligomerization domain (NOD)-like receptor protein 3 (NLRP3) related inflammasome components in specific regions of the central nervous system in different ALS models, but the cellular spatiotemporal evolution of this canonical inflammasome pathway and pyroptosis during ALS progression are unclear.</AbstractText><AbstractText Label="METHODS">The spinal cords of hSOD1<sup>G93A</sup> mice (ALS mice) and age-matched littermates (CON mice) were dissected at pre-symptomatic stage (60 d), early- symptomatic stage (95 d), symptomatic stage (108 d) and late-symptomatic stage (122 d) of the disease. By using Nissl staining, double immunofluorescence labelling, qRT-PCR or western blot, we detected morphology change and the expression, cellular location of GSDMD, NLRP3, caspase-1 and IL-1&#x3b2; in the ventral horn of lumbar spinal cords over the course of disease.</AbstractText><AbstractText Label="RESULTS">Neural morphology changes and GSDMD<sup>+</sup>/NeuN<sup>+</sup> double positive cells were observed in ventral horn from ALS mice even at 60 d of age, even though there were no changes of GSDMD mRNA and protein expressions at this stage compared with CON mice. With disease progression, compared with age-matched CON mice, increased expressions of GSDMD, NLRP3, activated caspase-1 and IL-1&#x3b2; were detected. Double immunofluorescence labeling revealed that NLRP3, caspase-1, IL-1&#x3b2; positive signals mainly localized in ventral horn neurons at pre- and early-symptomatic stages. From symptomatic stage to late-symptomatic stage, robust positive signals were co-expressed in reactive astrocytes and microglia.</AbstractText><AbstractText Label="CONCLUSIONS">Early activation of the canonical NLRP3 inflammasome induced pyroptosis in ventral horn neurons, which may participate in motor neuron degeneration and initiate neuroinflammatory processes during ALS progression.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Haoyun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Weifang Medical University, No. 7166 Baotong West Street, Weifang, 261053, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurologic Disorders and Regenerative Repair Lab of Shandong Higher Education, Weifang Medical University, No. 7166 Baotong West Street, Weifang, 261053, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Life Science and Technology, Weifang Medical University, No.7166 Baotong West Street, Weifang, 261053, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Bingkun</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Weifang Medical University, No. 7166 Baotong West Street, Weifang, 261053, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurologic Disorders and Regenerative Repair Lab of Shandong Higher Education, Weifang Medical University, No. 7166 Baotong West Street, Weifang, 261053, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shaoye</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Life Science and Technology, Weifang Medical University, No.7166 Baotong West Street, Weifang, 261053, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Life Science and Technology, Weifang Medical University, No.7166 Baotong West Street, Weifang, 261053, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Fandi</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Weifang Medical University, No. 7166 Baotong West Street, Weifang, 261053, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurologic Disorders and Regenerative Repair Lab of Shandong Higher Education, Weifang Medical University, No. 7166 Baotong West Street, Weifang, 261053, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yanchun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Weifang Medical University, No. 7166 Baotong West Street, Weifang, 261053, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurologic Disorders and Regenerative Repair Lab of Shandong Higher Education, Weifang Medical University, No. 7166 Baotong West Street, Weifang, 261053, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Fenghua</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Weifang Medical University, No. 7166 Baotong West Street, Weifang, 261053, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurologic Disorders and Regenerative Repair Lab of Shandong Higher Education, Weifang Medical University, No. 7166 Baotong West Street, Weifang, 261053, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Yingjun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Weifang Medical University, No. 7166 Baotong West Street, Weifang, 261053, Shandong, China. guanyj@wfmc.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurologic Disorders and Regenerative Repair Lab of Shandong Higher Education, Weifang Medical University, No. 7166 Baotong West Street, Weifang, 261053, Shandong, China. guanyj@wfmc.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Ave, Boston, MA, 02115, USA. xwang@rics.bwh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Neurosci</MedlineTA><NlmUniqueID>100966986</NlmUniqueID><ISSNLinking>1471-2202</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071199">NLR Family, Pyrin Domain-Containing 3 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D020169">Caspases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058847" MajorTopicYN="Y">Inflammasomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071199" MajorTopicYN="N">NLR Family, Pyrin Domain-Containing 3 Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069292" MajorTopicYN="N">Pyroptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Inflammasome</Keyword><Keyword MajorTopicYN="N">Neurodegeneration</Keyword><Keyword MajorTopicYN="N">Neuroinflammation</Keyword><Keyword MajorTopicYN="N">Pyroptosis</Keyword></KeywordList><CoiStatement>The authors have no relevant financial or non-financial interests to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>9</Day><Hour>23</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35945502</ArticleId><ArticleId IdType="pmc">PMC9364624</ArticleId><ArticleId IdType="doi">10.1186/s12868-022-00733-9</ArticleId><ArticleId IdType="pii">10.1186/s12868-022-00733-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gordon PH. Amyotrophic lateral sclerosis: pathophysiology, diagnosis and management. CNS Drugs. 2011;25(1):1&#x2013;15. doi: 10.2165/11586000-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11586000-000000000-00000</ArticleId><ArticleId IdType="pubmed">21128691</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Gordon PH. Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole. Ther Clin Risk Manag. 2012;8:359&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431958</ArticleId><ArticleId IdType="pubmed">22956874</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Fotinos A, Wu Q, Chen Y, Zhu Y, Baranov S, Tu Y, Zhou EW, Sinha B, Kristal BS, et al. N-acetyl-L-tryptophan delays disease onset and extends survival in an amyotrophic lateral sclerosis transgenic mouse model. Neurobiol Dis. 2015;80:93&#x2013;103. doi: 10.1016/j.nbd.2015.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.05.002</ArticleId><ArticleId IdType="pubmed">25986728</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal S, Tiwari A, Sharma K, Sharma SK. Does conserved domain SOD1 mutation has any role in ALS severity and therapeutic outcome? BMC Neurosci. 2020;21(1):42. doi: 10.1186/s12868-020-00591-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12868-020-00591-3</ArticleId><ArticleId IdType="pmc">PMC7547430</ArticleId><ArticleId IdType="pubmed">33036560</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362(6415):59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 2019;18(2):211&#x2013;220. doi: 10.1016/S1474-4422(18)30394-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30394-6</ArticleId><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Evavold CL, Kagan JC. Defying Death: the (W)hole truth about the fate of GSDMD pores. Immunity. 2019;50(1):15&#x2013;17. doi: 10.1016/j.immuni.2018.12.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.12.032</ArticleId><ArticleId IdType="pmc">PMC6710622</ArticleId><ArticleId IdType="pubmed">30650374</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Gao W, Shao F. Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci. 2017;42(4):245&#x2013;254. doi: 10.1016/j.tibs.2016.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2016.10.004</ArticleId><ArticleId IdType="pubmed">27932073</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao EA, Rajan JV, Aderem A. Caspase-1-induced pyroptotic cell death. Immunol Rev. 2011;243(1):206&#x2013;214. doi: 10.1111/j.1600-065X.2011.01044.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2011.01044.x</ArticleId><ArticleId IdType="pmc">PMC3609431</ArticleId><ArticleId IdType="pubmed">21884178</ArticleId></ArticleIdList></Reference><Reference><Citation>Platnich JM, Muruve DA. NOD-like receptors and inflammasomes: a review of their canonical and non-canonical signaling pathways. Arch Biochem Biophys. 2019;670:4&#x2013;14. doi: 10.1016/j.abb.2019.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2019.02.008</ArticleId><ArticleId IdType="pubmed">30772258</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie BA, Dixit VM, Power C. Fiery cell death: pyroptosis in the central nervous system. Trends Neurosci. 2020;43(1):55&#x2013;73. doi: 10.1016/j.tins.2019.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2019.11.005</ArticleId><ArticleId IdType="pubmed">31843293</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Z, Pan K, Pan J, Peng Q, Wang Y. The possibility and molecular mechanisms of cell pyroptosis after cerebral ischemia. Neurosci Bull. 2018;34(6):1131&#x2013;1136. doi: 10.1007/s12264-018-0294-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12264-018-0294-7</ArticleId><ArticleId IdType="pmc">PMC6246843</ArticleId><ArticleId IdType="pubmed">30306532</ArticleId></ArticleIdList></Reference><Reference><Citation>Baroja-Mazo A, Martin-Sanchez F, Gomez AI, Martinez CM, Amores-Iniesta J, Compan V, Barbera-Cremades M, Yague J, Ruiz-Ortiz E, Anton J, et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol. 2014;15(8):738&#x2013;748. doi: 10.1038/ni.2919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2919</ArticleId><ArticleId IdType="pubmed">24952504</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesavardhana S, Kanneganti TD. Mechanisms governing inflammasome activation, assembly and pyroptosis induction. Int Immunol. 2017;29(5):201&#x2013;210. doi: 10.1093/intimm/dxx018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxx018</ArticleId><ArticleId IdType="pmc">PMC5890894</ArticleId><ArticleId IdType="pubmed">28531279</ArticleId></ArticleIdList></Reference><Reference><Citation>Meissner F, Molawi K, Zychlinsky A. Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proc Natl Acad Sci U S A. 2010;107(29):13046&#x2013;13050. doi: 10.1073/pnas.1002396107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1002396107</ArticleId><ArticleId IdType="pmc">PMC2919927</ArticleId><ArticleId IdType="pubmed">20616033</ArticleId></ArticleIdList></Reference><Reference><Citation>Gugliandolo A, Giacoppo S, Bramanti P, Mazzon E. NLRP3 inflammasome activation in a transgenic amyotrophic lateral sclerosis model. Inflammation. 2018;41(1):93&#x2013;103. doi: 10.1007/s10753-017-0667-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-017-0667-5</ArticleId><ArticleId IdType="pubmed">28936769</ArticleId></ArticleIdList></Reference><Reference><Citation>Debye B, Schmulling L, Zhou L, Rune G, Beyer C, Johann S. Neurodegeneration and NLRP3 inflammasome expression in the anterior thalamus of SOD1 (G93A) ALS mice. Brain Pathol. 2018;28(1):14&#x2013;27. doi: 10.1111/bpa.12467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12467</ArticleId><ArticleId IdType="pmc">PMC8028558</ArticleId><ArticleId IdType="pubmed">27880990</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh JG, Muruve DA, Power C. Inflammasomes in the CNS. Nat Rev Neurosci. 2014;15(2):84&#x2013;97. doi: 10.1038/nrn3638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3638</ArticleId><ArticleId IdType="pubmed">24399084</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo ST, Baumann F, Ridall PG, Pettitt AN, Henderson RD, Bellingham MC, McCombe PA. The relationship between Bayesian motor unit number estimation and histological measurements of motor neurons in wild-type and SOD1(G93A) mice. Clin Neurophysiol. 2012;123(10):2080&#x2013;2091. doi: 10.1016/j.clinph.2012.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2012.01.028</ArticleId><ArticleId IdType="pubmed">22521362</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ, Olszewski AJ, Stieg PE, Lee JP, Przedborski S, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science. 2000;288(5464):335&#x2013;339. doi: 10.1126/science.288.5464.335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.288.5464.335</ArticleId><ArticleId IdType="pubmed">10764647</ArticleId></ArticleIdList></Reference><Reference><Citation>Italiani P, Carlesi C, Giungato P, Puxeddu I, Borroni B, Bossu P, Migliorini P, Siciliano G, Boraschi D. Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis. J Neuroinflammation. 2014;11:94. doi: 10.1186/1742-2094-11-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-94</ArticleId><ArticleId IdType="pmc">PMC4039322</ArticleId><ArticleId IdType="pubmed">24884937</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan Y, Han F. Key mechanisms and potential targets of the nlrp3 inflammasome in neurodegenerative diseases. Front Integr Neurosci. 2020;14:37. doi: 10.3389/fnint.2020.00037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnint.2020.00037</ArticleId><ArticleId IdType="pmc">PMC7393579</ArticleId><ArticleId IdType="pubmed">32792920</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019;20(13):3328. doi: 10.3390/ijms20133328.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20133328</ArticleId><ArticleId IdType="pmc">PMC6651423</ArticleId><ArticleId IdType="pubmed">31284572</ArticleId></ArticleIdList></Reference><Reference><Citation>Brotherton TE, Li Y, Cooper D, Gearing M, Julien JP, Rothstein JD, Boylan K, Glass JD. Localization of a toxic form of superoxide dismutase 1 protein to pathologically affected tissues in familial ALS. Proc Natl Acad Sci U S A. 2012;109(14):5505&#x2013;5510. doi: 10.1073/pnas.1115009109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1115009109</ArticleId><ArticleId IdType="pmc">PMC3325721</ArticleId><ArticleId IdType="pubmed">22431618</ArticleId></ArticleIdList></Reference><Reference><Citation>Albornoz EA, Woodruff TM, Gordon R. Inflammasomes in CNS diseases. Switzerland: Basel : Springer Basel AG; 2018. pp. 41&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">30536167</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadhim H, Deltenre P, Martin JJ, Sebire G. In-situ expression of Interleukin-18 and associated mediators in the human brain of sALS patients: Hypothesis for a role for immune-inflammatory mechanisms. Med Hypotheses. 2016;86:14&#x2013;17. doi: 10.1016/j.mehy.2015.11.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2015.11.022</ArticleId><ArticleId IdType="pubmed">26804591</ArticleId></ArticleIdList></Reference><Reference><Citation>Deora V, Lee JD, Albornoz EA, McAlary L, Jagaraj CJ, Robertson AAB, Atkin JD, Cooper MA, Schroder K, Yerbury JJ, et al. The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins. Glia. 2020;68(2):407&#x2013;421. doi: 10.1002/glia.23728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23728</ArticleId><ArticleId IdType="pubmed">31596526</ArticleId></ArticleIdList></Reference><Reference><Citation>Johann S, Heitzer M, Kanagaratnam M, Goswami A, Rizo T, Weis J, Troost D, Beyer C. NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients. Glia. 2015;63(12):2260&#x2013;2273. doi: 10.1002/glia.22891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22891</ArticleId><ArticleId IdType="pubmed">26200799</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabowski GA. Overview of Inflammation in neurometabolic diseases. Semin Pediatr Neurol. 2017;24(3):207&#x2013;213. doi: 10.1016/j.spen.2017.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.spen.2017.08.005</ArticleId><ArticleId IdType="pubmed">29103428</ArticleId></ArticleIdList></Reference><Reference><Citation>Baidya F, Bohra M, Datta A, Sarmah D, Shah B, Jagtap P, Raut S, Sarkar A, Singh U, Kalia K, et al. Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases. Immunology. 2021;162(2):160&#x2013;178. doi: 10.1111/imm.13264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13264</ArticleId><ArticleId IdType="pmc">PMC7808166</ArticleId><ArticleId IdType="pubmed">32939758</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon R, Albornoz EA, Christie DC, Langley MR, Kumar V, Mantovani S, Robertson AAB, Butler MS, Rowe DB, O&#x2019;Neill LA, et al. Inflammasome inhibition prevents alpha-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med. 2018;10(465) 10.1126/scitranslmed.aah4066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6483075</ArticleId><ArticleId IdType="pubmed">30381407</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Yuan YH, Chen NH, Wang HB. The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson's disease. Int Immunopharmacol. 2019;67:458&#x2013;464. doi: 10.1016/j.intimp.2018.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2018.12.019</ArticleId><ArticleId IdType="pubmed">30594776</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N, Sun C, Zheng M, Liu S, Shi R. Amentoflavone suppresses amyloid beta1-42 neurotoxicity in Alzheimer's disease through the inhibition of pyroptosis. Life Sci. 2019;239:117043. doi: 10.1016/j.lfs.2019.117043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2019.117043</ArticleId><ArticleId IdType="pubmed">31722188</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, McManus RM, Latz E. Inflammasome signalling in brain function and neurodegenerative disease. Nat Rev Neurosci. 2018;19(10):610&#x2013;621. doi: 10.1038/s41583-018-0055-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-018-0055-7</ArticleId><ArticleId IdType="pubmed">30206330</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan YL, Yuan Y, Tian L. Microglial regional heterogeneity and its role in the brain. Mol Psychiatry. 2020;25(2):351&#x2013;367. doi: 10.1038/s41380-019-0609-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-019-0609-8</ArticleId><ArticleId IdType="pmc">PMC6974435</ArticleId><ArticleId IdType="pubmed">31772305</ArticleId></ArticleIdList></Reference><Reference><Citation>Refolo V, Stefanova N. Neuroinflammation and glial phenotypic changes in alpha-synucleinopathies. Front Cell Neurosci. 2019;13:263. doi: 10.3389/fncel.2019.00263.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00263</ArticleId><ArticleId IdType="pmc">PMC6585624</ArticleId><ArticleId IdType="pubmed">31263402</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>